Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Comment by GunnerGon Jul 06, 2020 7:50pm
51 Views
Post# 31231460

RE:RE:RE:RE:RE:we already have several pieces of news incoming this quarter

RE:RE:RE:RE:RE:we already have several pieces of news incoming this quarterYou can find so many of these NR with fixed dates provided and they have missed so many of the dates.  What is your point?  

They should just say nothing and surprise all when  they finally submit it.  This is the third date provided by "New Management" as the NewcamoRealstups IDs liked to tell us not long ago.



ualcin1 wrote:

In its June 30 PR, Liminal states the following:

 

“We now expect the following timing for two important priorities of the Company for 2020:

  • The re-submission of our biologics licensing application (BLA) with the US Food and Drug Administration (FDA) for Ryplazim® (plasminogen) for the treatment of congenital plasminogen deficiency is anticipated to be filed in the third quarter of 2020; and
  • Our multiple ascending dose (MAD) Phase 1 clinical study of fezagepras is expected to be initiated in the second half of 2020.”



<< Previous
Bullboard Posts
Next >>